Introduction
Numerous approaches have been taken in the quest to understand and combat infection with human immunodeficiency virus (HIV), which leads to the fatal acquired immunodeficiency syndrome (AIDS) (Fields, 1994) . Although extensive investigations have been performed and have yielded much information about HIV expression and regulation in vitro, such approaches are limited since they cannot duplicate effects mediated by cell-cell interactions and cytokine release from the many diverse cell types present in vivo. It is becoming widely accepted that in vivo animal models are essential (1) to study the temporal cascade of pathogenesis induced by the virus, (2) to study the effects of individual viral components within the context of a dynamic and constantly developing immune system and (3) to evaluate vaccine strategies and screen antiviral agents. To date the most appropriate AIDS model in animals is the simian immunodeficiency virus (SIV) infection of macaques (Letvin & King, 1990) . However, these monkeys are in relatively short supply and expensive to support. What is required is a small laboratory animal with a well characterized immune system and a physiology similar to humans. The mouse fulfils these criteria and costs less to breed and maintain. Unfortunately, the host range of HIV does not include the mouse (even transgenic mice expressing the human CD4 viral receptor; Lores et al., 1992) , nor is there a murine virus directly equivalent to HIV. Nevertheless, two different technologies have made the mouse applicable to HIV research: (1) the humanized severe combined immunodeficiency (SCID-hu) mouse which can serve as a host for and promote the growth of human lymphocytes over long periods of time (reviewed t Present address: Division of Molecular Genetics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
in McCune et al., 1991) ; (2) the transgenic mouse (reviewed in Kollias & Grosveld, 1992) in which the effects of single genes and their products can be examined throughout the developmental and adult life of the animal. This review charts the contribution of transgenic mice to HIV research.
Production and use of transgenic mice
The favoured method of transgenic mouse production is by direct micro-injection of cloned genes into the pronucleus of a fertilized egg (Hogan et al., 1986) although methods using embryonic stem cells have more recently been developed (Schedl et al., 1993) . After micro-injection, the male and female pronuclei fuse to form the nucleus of a single embryo and the manipulated cells are transferred to a foster mother where subsequent uterine implantation allows development to term. Stable integration of the injected DNA into the germline cells of the founder mouse allows the transgene to be transmitted to subsequent generations. The tissue specific and developmental patterns of transgene expression are determined by the regulatory elements (endogenous or heterologous to the gene coding sequences) contained within the injected DNA construct. In many cases this expression can be distorted by effects from genomic sequences near the site of t.ransgene integration (Dillon & Grosveld, 1993) . However, control elements known as LCRs (locus control regions) have been shown to confer chromosomal position independent, high level, tissue specific expression. In the case of the human #-globin locus LCR, high level, erythroid specific expression has been obtained (Grosveld et al., 1987) while high level T cell specific expression has been achieved through the use of the human CD2 gene LCR (Greaves et al., 1989) .
Previously, transgenic mice have been used to study gene expression and function in a biological environment that is difficult to reproduce in vitro. They have been of 0001-2394 © 1994 SGM particular advantage in immunological studies aimed at understanding T cell repertoire selection during thymic development (Bonneville et al., 1989; Ishida et al., 1990) . In organogenesis, transgenic mice have provided insight into the roles of homeobox gene loci during embryonic segmentation (Kessel et al., 1990; Whiting et al., 1991) . Systemic effects such as oncogenesis and the spread of turnouts have also been highlighted through the use of transgenes. In particular, synergistic effects leading to cancerous states have been elucidated by crossing of transgenic mice expressing different oncogenes (reviewed by Adams & Cory, 1991 ; Berns, 1991) .
Transgenic mice have also been used to study the interaction of whole viral genomes, as well as individual viral genes and products with endogenous cellular genes and proteins. Analysis has been performed with a variety of viruses, both DNA and RNA. Direct micro-injection of viral sequences overcomes the normally restrictive steps in the infection process such as species and cell specificity, cell entry and integration or replication. For example, transgenic mice harbouring the hepatitis B virus HBx gene (thought to encode a transactivator protein) have been found to succumb to hepatocellular carcinoma at very high penetrance (C. M. Kim et al., 1991) . The bell transactivator of human foamy virus has been implicated as the causative agent in the severe neurological syndrome found in transgenic mice expressing this region of the viral genome (Aguzzi, 1993) . Of the human retroviruses, the human T cell leukemia virus (HTLV)-I proviral genome has been extensively studied in transgenic mice. Numerous studies have demonstrated that the HTLV-1 Tax protein is a potent transactivator of cellular genes, e.g. IL-2, IL-2 receptor, c-fos, GM-CSF and several others (reviewed in Sodroski, 1992) . In transgenic mice, the tax gene expressed under the transcriptional control of the HTLV-1 long terminal repeat (LTR) results in the development of thymic aplasia, neurofibromas and an exocrinopathy of the salivary and lacrimal glands resembling Sjogren's syndrome (Nerenberg et al., 1987; Green et al., 1989) . Thus, transgenic mice can offer several distinct advantages for the in vivo analysis of the HIV genome: (1) they bypass the species-and tissue-specific infectability barriers; (2) they pose little or no risk in terms of biosafety; (3) they can reveal effects of individual HIV genes and proteins; (4) they can be interbred in various combinations to observe the synergistic effects of numerous HIV transgenes; and (5) they can yield a large statistical sampling.
HIV-1 complete proviral genome transgenics
To examine the in vivo consequences of HIV-1 viral proteins subsequent to the infection and integration process, direct micro-injection of the complete HIV-1 proviral genome into fertilized mouse eggs has been performed. Fig. 1 illustrates the complete HIV-1 genome and the genes encoding the structural and regulatory proteins. In the study by Leonard et al. (1988) , seven founder animals giving germline transmission of proviral DNA from an infectious HIV-1 clone were obtained. One of these founders produced HIV specific serum antibodies as measured in immunodetection assays. The founder was mated with non-transgenic animals and subsequent progeny developed disease characteristics followed by death at about 25 days after birth. The affected animals were 50 to 80 % of normal size and postmortem analysis revealed epidermal hyperplasia, lymphadenopathy, splenomegaly and pulmonary lymphoid infiltration. HIV particles were recovered from skin, spleen and lymph nodes of affected animals in this single line and were found to be infectious when tested on human cell lines. Unfortunately, a continuous line of mice could not be generated to examine whether the expression of HIV in this case may have been the result of integration next to a transcriptionally active gene in the chromosomal DNA.
Transgenic mice have also been obtained carrying defective (deletion mutant) HIV-1 proviral genomes. In one study, HIV-1 transcripts were found in several tissues (Iwakura et al., 1992) . Effects on lens fibre cells leading to cataracts were observed and immunoblot analysis revealed an accumulation of p24 Gag antigen in affected lenses. Whether these findings are coincidental or related remains to be elucidated. When a Gag-Pol deletion mutant HIV genome was used to produce three transgenic lines, specific expression of HIV was observed in the kidneys (Dickie et al., 1991) . These mice developed renal disease with proteinuria and exhibited a high mortality rate. The authors suggest that these transgene effects reflect the HIV associated nephropathy seen in infected patients. Another report of transgenic mice containing a replication defective HIV-1 proviral genome described the development of severe nephrotic syndrome and progressive glomerulosclerosis (Kopp et al., 1992) . Of the HIV proteins tested, only Rev was detectable in the sclerotic glomeruli. These mice were also found to develop proliferative epidermal lesions (Kopp et al., 1993) . Viral RNA was detected in the skin of these mice although the only viral protein identified was gpl20. The mechanism for the phenotype observed is not known but it appears that one or more of the viral gene products may promote epidermal cell proliferation.
In an attempt to produce high levels of all HIV proteins in vivo, provirus transgenic mice have been made in which the HIV promoter was replaced with the MMTV promoter (Jolicoeur et al., 1992) . High levels (as expected with the MMTV promoter) of the gp 160, gp 120 Env proteins and the p55, p24 Gag proteins were found in the mammary glands of four transgenic lines. Higher levels were found in lactating females. The p 160 Gag-Pol precursor was also found at low levels in the mammary glands. Although not analysed, Protease and Rev proteins are also assumed to have been produced since protein cleavage and splicing of HIV RNAs occurred. Interestingly, these mice exhibited none of the phenotypes described for the other proviral transgenics. This is most probably due to the specificity of the MMTV promoter for mammary tissue although some low level ectopic expression was observed.
HIV-1 LTR transgenics
Since individuals infected with HIV have a characteristically long period of clinical latency before the appearance of viral pathogenic effects, the events controlling the transcription of the integrated proviral genome are thought to be critical to this process. In vitro studies have suggested that cofactors such as cytokines (Rosenberg & Fauci, 1990) or u.v. light (Stein et al., 1989) are required for progressive infection by HIV as evidenced by HIV gene expression. Therefore many studies have focused on the regulatory elements and control of transcription from the HIV long terminal repeat (LTR) promoter. Transgenic mice generated with the HIV-1 LTR directing the expression of reporter genes such as the bacterial chloramphenicol transferase (CAT) gene (Khillan et al., 1988) or the secreted form of the human a-1 antitrypsin (a-l-AT) gene (Mehtali et al., 1992) have been examined for transactivated expression after cross-breeding with transgenic mice expressing the Tat transactivator in the lens of the eye or lymphoid tissue. A 5-fold increase in CAT expression in eye tissue (Khillian et al., 1988) and a 10 to 20-fold increase in serum a-l-AT levels (Mehtali et al., 1992) were found, indicating that the HIV-1 LTR is functional and transactivatible in mice.
HIV-1 LTR CAT transgenic mice have also been examined during pregnancy (Furth et al., 1990 ). An increase of 8 to 10-fold in CAT activity was noted in the placenta and uterus from day 11 to day 17 of pregnancy. The authors postulate from these results that hormonal induction of HIV-I expression may contribute to perinatal transmission of HIV. Other HIV-1 LTR CAT transgenic mice when exposed to u.v. radiation exhibit a strong indication of expression (up to 30-fold) in the skin (Frucht et al., 1991) . This has been confirmed in HIV-1 LTR Tat transgenics (Vogel et al., 1992) . These mice express the transgene selectively in the epidermal compartment of the skin. After exposure to u.v.-B and u.v.-C radiation, steady state LTR-Tat RNA levels increased up to 10-fold in skin tissue. A link between these studies and HIV expression in infected individuals cannot be established since the presence of HIV harbouring cells in human epidermis has not been described.
The pathogenesis of AIDS following HIV-1 infection is often accompanied by a neurological syndrome called AIDS dementia complex, ADC. Although significant loss of neurons has been observed in the brains of patients with ADC, HIV-1 replication in neurons has not been reported. To examine the expression of HIV-1 in the central nervous system (CNS) transgenic mice were constructed with the LTRs of two separate CNS derived strains of HIV-1 fused to a fl-galactosidase (LacZ) reporter gene (Corboy et al., 1992) . These mice expressed LacZ RNA and protein in multiple tissues most notably in various neuronal regions of the brain, retina and CNS. No previous studies using LTRs from non-CNS derived HIV-1 strains showed any such expression (Leonard et al., 1988; Vogel et al., 1988 Vogel et al., , 1992 Mehtali et al., 1992) . These studies have revealed a previously unknown phenomenon whereby the neuro-adapted LTRs of CNS derived HIV-1 can function in vivo in neurons.
HIV structural gene transgenics (gpl20) As noted above, many HIV-1 infected patients develop ADC without the presence of detectable virus within the neurons. This has prompted speculation that diffusable virus-derived or host factors cause this neurotoxicity (reviewed in Spencer & Price, 1992) . The HIV-I envelope glycoprotein, gpl20, is released from infected cells and the damaging effects of injected gpl20 on rat brains (Kimes et al., 1991 ; Glowa et al., 1992) have suggested it to be neurotoxic. In order to examine this effect in vivo, transgenic mice have been produced expressing gpl20 in brain tissue (Toggas et al., 1994) . The gpl20 coding sequence was placed under the control of a modified form of the murine glial fibrillary acidic protein (GFAP) gene. GFAP directed expression of the transgene predominantly to astrocytes which make up a large part of the CNS. Double labelling of brain sections with a gp 120 specific riboprobe and GFAP antibodies localized the gpl20 transgene expression to astrocytes. However, gpl20 protein could not be detected by immunostaining of brain tissue. Nevertheless, extensive CNS damage was observed in the GFAP-gpl20 transgenics but not in the non-transgenic controls. Neuropathological changes such as extensive vacuolizations of dendrites and large neuron loss were observed. The brains of transgenic mice exhibited widespread reactive astrocytosis which was more pronounced with higher levels of gp 120 expression. It remains to be established whether gpl20 is directly responsible for these effects or whether intermediate molecules are involved. These mice are potentially a very powerful model for HIV-1 related neuropathology and neuroprotective treatments.
HIV regulatory gene transgenics

Tat
The best characterized regulatory protein of HIV is Tat, which is a small nuclear protein expressed from several multiply spliced RNAs. When bound to the TAR sequence of viral RNA, Tat acts as a potent transactivator of transcription from the HIV LTR throughout initiation and elongation. During acute HIV-1 infection or after transfection of the Tat gene, Tat has been found as an extracellular protein which also has an effect on cell proliferation and function (Ensoli et al., 1990) . In this extracellular form, Tat stimulates the growth of spindlelike cells derived from Kaposi's sarcoma (KS) lesions in AiDS patients. In addition, extracellular Tat has been shown to be taken into the nucleus by cultured cell lines resulting in transcellular transactivated expression from the HIV-1 LTR (Frankel & Pabo, 1988; Helland et al., 1991) .
Inhibition of the antigen-specific response of T cells has been ascribed as another Tat-mediated effect (Viscidi et al., 1989; Subramanyam et al., 1993) . Recombinant Tat protein was shown to inhibit antigen specific proliferation of human peripheral blood lymphocytes but to have no effect on polyclonal mitogen responses. This inhibition could be due to Tat-mediated induction of immunosuppressive cytokines. TGF-fll, which is known to have immunosuppressive functions including an anti-proliferative effect on T and B cells (reviewed in Massague, 1990) , has been shown to be significantly elevated in the brains of HIV-1 infected individuals (Wahl et al., 1991) . Transfection of the Tat gene or the direct addition of Tat protein to human astrocytic glial cells (Cupp et al., 1993) transactivates transcription from the TGF-pl promoter. Since TGF-fll is known to be a chemotactic agent for monocytes, these authors suggest that this could lead to further recruitment of infected monocytes into the brain and added CNS dysfunction.
Several other cytokines have been shown to be elevated in the serum or produced at high levels by cultured lymphocytes of HIV-1 infected individuals (Merrill et al., 1989; Breen et al., 1990) . Tat introduced into a human B cell line induced an 8-fold increase in tumour necrosis factor (TNF)-fl mRNA and an even greater increase in TNF-fl protein levels (Sastry et al., 1990) . This effect on TNF-fl expression has been confirmed on mitogen stimulated Tat-transfected or HIV-1 infected T cells (Buonaguro et al., 1992) . TNF upregulates other cytokines, most notably IL-1 and IL-6 (Locksley et al., 1987; Sanceau et al., 1991) . Tat has also been reported to upregulate the IL-4 receptor on a human B cell line (Purl & Aggarwal, 1992) and to repress major histocompatibility complex class I gene promoter activity (Howcroft et al., 1993) , possibly providing a mechanism for the virus to evade HIV-1 specific cytotoxic T lymphocytes. Other Tat-mediated effects on cellular genes and proteins are as follows; downregulation of interferon induced p68 kinase which is thought to have an antivlral activity (Roy et al., 1990) , repression of manganese superoxide dismutase expression in HeLa cells (Flores et al., 1993) , activation of extracellular matrix proteins in glioblastoma cells (Taylor et al,, 1992) , cytotoxicity to lymphocytes (Benjouad et al., 1993) and interference with tumour angiogenesis when expressed in a cell line transplanted into nude mice (Huber et al., 1992) .
From the above reports, the implied mechanism of Tat-mediated regulation of human cellular gene expression is through its action as a transcription factor. It has been suggested that the transactivation activity of Tat occurs in human but not mouse cells since a region on human chromosome 12 is thought to be required for this action (Hart et al., 1989; Newstein et al., 1990) . However, other workers have shown high levels of transactivation in mouse cell lines (Barry et al., 1991; Dillon et al., 1991 ; Mehtali et al., 1992) . Thus, transgenic mice can be used to test the in vivo relevance of these Tat mediated effects.
Transgenic mice expressing the HIV-1 Tat gene under the control of the HIV-1 LTR have been described. In such mice, HIV-1 LTR driven reporter constructs are transactivated by up to 20-fold (Khillan et al., 1988; Mehtali et al., 1992) demonstrating that Tat activity is not species specific. These mice developed skin lesions which had similar characteristics to KS lesions of human AIDS patients (Vogel et al., 1988) . Signs of epidermal hyperplasia and appearance of dermal lesions were found in male mice after observation periods of 1 year or longer. The development of KS-like skin lesions in these transgenic mice coincides with the growth stimulation of KS cells seen with Tat in vitro. However, a direct role for Tat in KS has not been proven. An increased incidence of liver cancer was also found in these male Tat transgenics over 18 months of age (Vogel et al., 1991) . These results may be only peripherally relevant to the in vivo human situation since the CD4 ÷ cells for which HIV has tropism, did not express the Tat transgene (Tat RNA expression was not detected in the thymus), although the effects may be due to extracellular Tat. Another recent study, in which transgenic mice were generated using a region of the BK polyoma virus early region promoter to express Tat, resulted in endothelial cell proliferation and tumour formation in animals of 15 to 22 months (Corallini et at., 1993) . The expression pattern of the transgene in these animals was not properly defined. 
Nef
The function of the Nef gene product and its precise role in the viral life cycle is not yet fully understood. Nef is encoded by up to 80 % of the early, multiply spliced class of viral transcripts (Robert-Guroff et al., 1990) . The Nef gene product was initially reported to downregulate the level of viral replication in cultured T cells (Terwilliger et al., 1986; Luciw et al., 1987) and act as a repressor of HIV-I LTR transcription (Ahmad & Venkatesan, 1988; Niederman et al., 1989) . However, others have failed to demonstrate the negative effects of Nef on viral transcription and replication in vitro (Hammes et al., 1989; S. Kim et al., 1989; Luria et al., 1991) , and more recently Nef has been shown to accelerate viral replication in primary lymphocytes (de Ronde et al., 1992) . In addition, the Nef protein has been reported to inhibit the DNA binding activity of the inducible transcription factors AP1 (Neiderman et al., 1993) and NF-KB (Neiderman et at., 1992) , reducing transcription from the IL-2 promoter (which contains NF-xB binding sites) up to 20-fold (Luria et al., 1991) . The conflicting results concerning the effects of Nef on transcription may be due to the use of immortalized cell lines in these in vitro investigations; for these reasons, experiments in vivo in animal models should give a more realistic picture.
A significant advance in this direction was observed in SIV-infected Rhesus macaques (Kestler et al., 1991) . In this study, the requirement for a full open reading frame of the SIV Nef gene for efficient viral replication and pathogenesis in vivo was demonstrated. While no detectable difference in the rate of replication in cultured T cells was observed for any of the Nef mutant viruses, in vivo there appears to be a strong selective pressure for virus which encodes a full length Nef protein. These results suggest a major role for the Nef gene in the in vivo life cycle of the virus, presumably via an interaction with the host immune system.
To support this, the Nef gene expressed in vitro in the absence of other HIV sequences was shown to downregulate cell surface levels of CD4 on T, B and macrophage/monocyte cell lines (Guy et al., 1987; Garcia & Miller, 1991; Mariani & Skowronski, 1993) . This effect is not species specific, is independent of protein kinase C-dependent phosphorylation of serine residues on CD4 and requires the cytoplasmic domain of the CD4 molecule (Garcia et al., 1993; Garcia & Miller, 1991) . Nef was suggested to induce a post-translational modification to the CD4 surface expression pathway (Garcia & Miller, 1991) since the steady state levels of CD4 mRNA and protein were unaffected.
To examine the possibility of various Nef-induced cellular changes on the immune system of an infected individual, expression of the Nef gene was directed to the T cells of the in vivo immune system of transgenic mice. Two different alleles of the Nef gene under the control of the human CD2 T cell specific regulatory elements and its LCR (Brady et al., 1993) have been used. Numerous lines of transgenic mice exhibited a marked downregulation in the level of CD4 on the surface of double positive (DP) thymocytes and a decrease in the number of single positive (SP) cells in the thymus. The loss of SP cells is most likely due to aberrant positive selection on CD4 downregulated DP thymocytes. The downregulated CD4 is held intracellularly and co-localizes to the Golgi but not the endoplasmic reticulum. This suggests that Nef may directly interact with CD4 to block its progression to the cell surface, or that Nefhas an indirect effect on proteins necessary for mediating cell surface expression of CD4. Functional analysis in these mice revealed a decrease in total activation levels of transgenic thymocytes when polyclonally stimulated through the T cell receptor complex. Similarly, transgenic mice expressing the Nef gene under the T cell specific control of the murine CD3 regulatory elements have also been made (Skowronski et al., 1993) . The general phenotype was similar to the mice described above regarding the effects of Nef on CD4 levels of thymocytes and the reduction of SP CD4 cells in the thymus. However, this report showed a dramatic increase in the level of thymocyte activation and proliferation in response to polyclonal stimulation through the T cell receptor. Although preliminary, these results suggest different degrees of Nef mediated effects on the maturing population of CD4 + cells. Further avenues of research using transgenic mice that express the Nef gene under the control of other T cell specific regulatory elements should allow the effects of the Nef protein to be directed toward specific developmental subsets of CD4 ÷ cells in the murine system.
Rev
Rev is a small nuclear regulatory protein of HIV expressed from multiply spliced RNAs. It binds specifically to a highly structured RNA element, the Rev response element (RRE). Rev is not a transcriptional transactivator but allows the synthesis of late viral proteins from incompletely spliced HIV mRNAs (reviewed in Cullen, 1992) .
As yet, little evidence exists for the effects of Rev on cellular genes and proteins. A single tightly associated Rev binding protein, B23 (a mammalian nucleolar protein), was identified by passing cell nuclear extracts down a Rev affinity column (Frankhauser et al., 1991) . Despite high affinity binding, the addition of RRE DNA displaced B23 from Rev. Since B23 functions as a shuttle for ribosomal protein into the nucleus, it could also help return Rev to the nucleus or nucleolus for further rounds of RNA export. Recently, the eukaryotic translation initiation factor 5A (eIF-5A) has been shown to bind specifically to the Rev activation domain suggesting that this interaction is critical, targeting RRE containing RNA to the cellular translational machinery (Ruhl et al., 1993) . It would be interesting to examine the action of Rev in vivo but this is complicated by the fact that Rev does not seem to function in non-human cells (Trono & Baltimore, 1990) . However, there may be an effect of Rev in mouse cells as evidenced in transgenic mice made by injection of a replication defective HIV-1 proviral DNA construct (Kopp et al., 1992) . These mice develop severe nephrotic syndrome followed by rapid progression to end-stage renal failure. Rev protein was shown to be expressed in the sclerotic glomeruli. Transgenic mice specifically overexpressing Rev in CD4 + T cells have not been reported.
Vpu, Vif and Vpr
The three other conserved HIV-1 regulatory proteins (Vif, Vpr and Vpu) are translated from late, incompletely spliced mRNAs (Schwartz et al., 1990 (Schwartz et al., , 1991 and are thought to be involved in the formation and release of infectious viral particles.
Vpu is not essential for HIV-1 replication in cell lines (Klimkait et al., 1990) . However, T cells infected with Vpu-positive virus release 3-to 5-fold more virions than those infected with an isogenic Vpu-negative virus (Klimkait et al., 1990) . Vpu has been shown to interact with cellular processes. It appears to induce rapid degradation of CD4 complexed to gp 160 Env protein in the endoplasmic reticulum (ER) (Willey et al., 1988) significantly decreasing the half-life of CD4/gpl60 from 6 h to 12 min (Willey et al., 1992) . Thus, HIV-1 has at least two distinct mechanisms to downregulate cell surface CD4; Vpu and Nef. The in vivo downregulation of CD4 in Nef transgenic mice strongly supports the use of such an in vivo model for Vpu. Generation and mating of gpl60 and Vpu transgenic mice expressing these respective proteins in CD4 + cells could yield further interesting insights into the mechanism of CD4 downregulation.
Very little is known about the function of Vif or Vpr. Initial studies have shown that Vif defective HIV-1 strains infect cells 103-fold less efficiently than wild-type viruses (Fisher et al., 1987 ; Strebel et al., 1987) . Recently, Vif has been shown to be crucial for the synthesis of proviral DNA inside the infected cell, but not to have a direct role in cytopathicity (von Schwedler et al., 1993) . Vpr is found in HIV-1 virions at molar amounts equivalent to that of Gag, although it is not a viral structural protein (Cohen et al., 1990) . Its role in HIV-I replication is unclear, but Vpr has been implicated in the differentiation and growth inhibition of cell lines derived from rhabdomyosarcomas, which are tumours of muscle cell origin (Levy et al., 1993) . The mechanism of these events and the function of this protein is not known. To date, no transgenic mice have been generated with Vpu, Vif or Vpr, although their effects in vivo may only be observed when in combination with other HIV proteins.
Conclusions
Research examining HIV-1 expression and its effects on cellular processes in vivo is currently a wide and expanding area. An understanding of the effects of the proteins expressed on HIV replication is clearly one important aspect of these investigations. However, the mechanisms by which HIV regulatory proteins affect cellular processes may lead to even more productive advances in approaches to alleviate the immuno-deficiencies induced by HIV infection. Many cellular interactions and effects have been identified but need further analysis to distinguish between the static effects produced in vitro and those seen with a dynamic in vivo model. Transgenic mice have already proven to be a powerful in vivo approach to study the effects of HIV-1 encoded proteins individually and in various combinations over long periods of time.
Generally, the strategy using the entire HIV genome in transgenic mouse experiments is interesting but perhaps limited due to the uncertainty of Rev function in mice. So far no transgenic lines of mice carrying the entire HIV proviral genome with expression originating from the HIV LTR have been shown to produce high levels of all HIV proteins. If Rev is defective and does not function in mouse cells as suggested by Trono & Baltimore (1990) , late HIV mRNAs could be held in unresolved splicing complexes (Chang & Sharp, 1989 ) and these proteins would not be produced. In addition, position effects related to chromosomal position of integration of the entire HIV genome or HIV LTR reporter gene constructs most likely have an influence on transgene expression. Retroviruses are known to integrate frequently in preferred sites in particular cell types (Shih et al., 1988) . These sites are usually transcriptionally active and allow expression from the proviral LTR. However, in the case of micro-injected proviral DNA, integration is random and often occurs in inactive regions of the host genome. This may explain the great variability in tissue specific expression and some of the difficulties in reproducing phenotypic effects observed in transgenic mice relying on the HIV promoter for transcription. Furthermore, expression in these mice occurs predominantly in tissues and in cells (CD4-) that would not be susceptible to HIV infection.
While constructs with promoters (e.g. MMTV) known to direct higher levels of transgene expression in mice have been used to express HIV genes, more relevant expression cassettes (CD2, CD3) directing high level tissue specific transcription in CD4 + cells are yielding results on HIV related effects in the host immune response. Such cassettes usually incorporate LCR elements, enhancers and/or introns and exogenous polyadenylation signals so as to increase expression and stabilize transgene RNA. These transgenic approaches have been very successful and have provided insight into the effects of Nef in the downregulation of CD4, confirming some of the in vitro studies. The advantage of expressing Nef in an in vivo model is in the dynamic and developing immune system, where positive selection in the thymus was found to be affected. Such results may suggest a mechanism by which CD4 + cells are progressively depleted in AIDS patients. Further data on CD4 downregulation could be obtained by directing Nef expression exclusively to peripheral T cells or creation of Vpu transgenic mice in combination with gpl60 transgenic mice. Direct cellular interactions of Rev and Vif may also be elucidated from this multiple transgenic approach. As with the Nef studies, the use of T cell specific expression elements for the Tat gene will be particularly informative in the examination of its effect on antigen mediated proliferation (as seen in vitro) and on the wide range of responses from various cytokine genes. Additionally, if the differentiation induced by Vpr in rhabdomyosarcoma cells proves to be a general phenomenon, Vpr transgenic mice in which expression is directed to lineages other than the T cell lineage should be of tremendous interest.
CNS directed expression in transgenic mice has yielded insight into the neurological changes induced by HIV. The use of the GFAP gene control element to express gpl20 resulted in extensive in vivo neuron loss. Further use of this expression cassette in transgenic mice can help elucidate the neuropathogenic effects of other HIV proteins as well as the cofactors which may hasten the onset of HIV related CNS damage.
Finally, transgenic mice could also be a useful assay system for demonstrating the efficacy of therapeutic strategies (drug or molecular) directed at the inhibition of viral replication and interference with viral regulatory proteins. Tat mediated inhibition approaches with drugs, DNAs or RNAs have been reviewed in Johnston & Hoth (1993) and specific retroviral based systems delivering TAR RNA decoys (Sullenger et al., 1990) , Tat mediated conditional cell ablation (Brady et al., 1994) and transdominant mutant Tat protein (Pearson et al., 1990) have been demonstrated only in vitro. Also, drug testing (such as anti-Nef compounds to reverse CD4 downregulation and T cell depletion or protease inhibitors) cannot be performed in vitro. Transgenic mice should serve as a model test system for the efficiency of these approaches in vivo.
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